相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
Richard K. Yang et al.
JOURNAL OF IMMUNOLOGY (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer
Zachary D. Horne et al.
JOURNAL OF SURGICAL RESEARCH (2011)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado et al.
CANCER RESEARCH (2010)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
Antoni Ribas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Intratumoral immunocytokine treatment results in enhanced antitumor effects
Erik E. Johnson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma
Rebecca C. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells
M Karimi et al.
JOURNAL OF IMMUNOLOGY (2005)
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
MR Verneris et al.
BLOOD (2004)
Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
ZC Neal et al.
CLINICAL CANCER RESEARCH (2004)
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
DM King et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8+ T cells
CW McMahon et al.
JOURNAL OF IMMUNOLOGY (2002)
Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation
RE Vance et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
